ID: ALA4290253

Max Phase: Preclinical

Molecular Formula: C17H28N2O8

Molecular Weight: 388.42

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCCC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CNC(C)=O)OC(C(=O)O)=C[C@@H]1O

Standard InChI:  InChI=1S/C17H28N2O8/c1-3-4-5-6-13(23)19-14-10(21)7-12(17(25)26)27-16(14)15(24)11(22)8-18-9(2)20/h7,10-11,14-16,21-22,24H,3-6,8H2,1-2H3,(H,18,20)(H,19,23)(H,25,26)/t10-,11+,14+,15+,16+/m0/s1

Standard InChI Key:  NLZZGCLVJKTGEH-IQVWLFHZSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 388.42

Molecular Weight (Monoisotopic): 388.1846

AlogP: -1.36

#Rotatable Bonds: 10

Polar Surface Area: 165.42

Molecular Species: ACID

HBA: 7

HBD: 6

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 3.20

CX Basic pKa:

CX LogP: -1.94

CX LogD: -5.39

Aromatic Rings: 0

Heavy Atoms: 27

QED Weighted: 0.25

Np Likeness Score: 0.86

References

1. Guo T, Héon-Roberts R, Zou C, Zheng R, Pshezhetsky AV, Cairo CW..  (2018)  Selective Inhibitors of Human Neuraminidase 1 (NEU1).,  61  (24): [PMID:30457869] [10.1021/acs.jmedchem.8b01411]

2.  (2018)  Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase, 

Source

Source(2):

• Scientific Literature
• Patent Bioactivity Data